Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRx0518 in Patients With Solid Tumour Awaiting Surgical Removal
NCT03934827Phase 1Unknown
- Sponsor
- Imperial College London
- Start
- Apr 2019
- Primary completion
- Dec 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MRx0518 in melanoma, breast cancer, uterine cancer and 7 more (2 arms), sponsored by Imperial College London. Primary endpoints: Adverse Events and Serious Adverse Events, Clinically significant changes in biochemistry, haematology and urinalysis laboratory results and 3 more. Status: unknown.
02
Drugs
MRx0518
03
Conditions
melanomabreast canceruterine cancerovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT03934827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934827.